260 related articles for article (PubMed ID: 23650428)
1. Cancer drugs in the United States: Justum Pretium--the just price.
Kantarjian HM; Fojo T; Mathisen M; Zwelling LA
J Clin Oncol; 2013 Oct; 31(28):3600-4. PubMed ID: 23650428
[No Abstract] [Full Text] [Related]
2. Challenging the soaring price of cancer medicines: a call for equity and transparency.
Gonçalves A; Maraninchi D; Vernant JP
Ann Oncol; 2016 Sep; 27(9):1812-3. PubMed ID: 27154419
[No Abstract] [Full Text] [Related]
3. Cancer drug prices and the free-market forces.
Kantarjian H; Zwelling L
Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
[No Abstract] [Full Text] [Related]
4. Market spiral pricing of cancer drugs.
Light DW; Kantarjian H
Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
[No Abstract] [Full Text] [Related]
5. The just price of cancer drugs and the growing cost of cancer care: oncologists need to be part of the solution.
Pfister DG
J Clin Oncol; 2013 Oct; 31(28):3487-9. PubMed ID: 24002517
[No Abstract] [Full Text] [Related]
6. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
7. Can treatment costs be tamed?
Malakoff D
Science; 2011 Mar; 331(6024):1545-7. PubMed ID: 21436438
[No Abstract] [Full Text] [Related]
8. US hospitals object to changes in Genentech drug distribution.
Furlow B
Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
[No Abstract] [Full Text] [Related]
9. Cancer Drugs: An International Comparison of Postlicensing Price Inflation.
Savage P; Mahmoud S; Patel Y; Kantarjian H
J Oncol Pract; 2017 Jun; 13(6):e538-e542. PubMed ID: 28605615
[TBL] [Abstract][Full Text] [Related]
10. Soaring price of cancer drugs leads plans to new approaches.
Sipkoff M
Manag Care; 2007 Aug; 16(8):12-3. PubMed ID: 17886533
[No Abstract] [Full Text] [Related]
11. Cost effectiveness and cancer drugs.
Battley JE; Connell LC; Graham DM; O'Reilly S
J Clin Oncol; 2014 Apr; 32(10):1091-2. PubMed ID: 24590642
[No Abstract] [Full Text] [Related]
12. Health policy: Putting a price on cancer.
Sullivan R; Aggarwal A
Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
[No Abstract] [Full Text] [Related]
13. The high cost of cancer drugs and what we can do about it.
Siddiqui M; Rajkumar SV
Mayo Clin Proc; 2012 Oct; 87(10):935-43. PubMed ID: 23036669
[No Abstract] [Full Text] [Related]
14. Cancer Drugs Fund of minimal benefit.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
[No Abstract] [Full Text] [Related]
15. Monthly and Median Costs of Cancer Drugs at the Time of FDA Approval 1965-2016.
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 29117395
[No Abstract] [Full Text] [Related]
16. The UK Cancer Drugs Fund Experiment and the US Cancer Drug Cost Problem: Bearing the Cost of Cancer Drugs Until It Is Unbearable.
Prasad V; Mailankody S
Mayo Clin Proc; 2016 Jun; 91(6):707-12. PubMed ID: 27261866
[No Abstract] [Full Text] [Related]
17. Role of the 340B Drug Discount Program in Recent Cancer Care Trends.
Kantarjian HM; Chapman R
J Oncol Pract; 2015 Jul; 11(4):303-7. PubMed ID: 26036268
[TBL] [Abstract][Full Text] [Related]
18. Why clinical oncologists should talk about the price of cancer drugs.
Berlinger N
Virtual Mentor; 2013 Aug; 15(8):677-80. PubMed ID: 23937783
[No Abstract] [Full Text] [Related]
19. Oral/infusion cancer drug parity begins to raise health plan costs.
Carroll J
Manag Care; 2012 Jan; 21(1):7-8. PubMed ID: 22334937
[No Abstract] [Full Text] [Related]
20. Cancer Care Under the Biden Administration.
Dusetzina SB
JAMA; 2021 Feb; 325(6):527-528. PubMed ID: 33560329
[No Abstract] [Full Text] [Related]
[Next] [New Search]
